CN
CNTX
Context Therapeutics Inc.
$2.37
+6.05%
$204.9M
No data for this timeframe.
Vol
Market Cap$204.9M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders3 funds
Inst. Value$6.3M
Inst. Activity2 buys / 0 sells
Reddit Sentiment40° Cool
SEC Reports3
Press Releases2
Recent Activity
May 18, 2026
contract
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
<p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange
May 6, 2026
SEC
Context Therapeutics reported Q1 2026 EPS of -$0.09, beating consensus of -$0.12 by 25%. The pre-revenue biotech highlig
PRESS-RELEASE — Impact 5/10
May 1, 2026
SEC
Context Therapeutics resolved a stockholder class action lawsuit challenging its charter provisions. Under a court-appro
8-K — Impact 2/10
Apr 2, 2026
SEC
Context Therapeutics Inc. (CNTX) announced that the FDA has granted Fast Track designation to its investigational drug C
8-K — Impact 7/10
Feb 19, 2026
Insider
Levit Alex C. sold 270,000 shares
Chief Legal Officer, Corp. Sec @ $0.00 ($0.00)
Feb 19, 2026
Insider
Minai-Azary Jennifer Lynn sold 275,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Feb 19, 2026
Insider
Chagin Karen Deborah sold 290,000 shares
Chief Medical Officer @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
508,329 shares ($747.2K)
Price Targets
$6.00
+153.7% upside
Strong Buy
Current $2.37
Low $4.00
Median $5.50
High $9.00
8 analysts
$4.00
$9.00
Analyst Ratings
4Strong Buy
11Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 24, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 24, 2026 | Guggenheim | REITERATE | Buy → Buy |
| Mar 24, 2026 | Piper Sandler | MAINTAIN | Overweight → Overweight |
| Dec 22, 2025 | Jones Trading | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.09 ▲ +20.3% | $-0.10 — $-0.07 | -1% YoY | 8 |
| Next Q | $-0.10 ▲ +15.6% | $-0.11 — $-0.07 | 3% YoY | 8 |
| Current FY | $-0.39 ▲ +15.7% | $-0.43 — $-0.30 | -3% YoY | 8 |
| Next FY | $-0.41 ▲ +11.1% | $-0.49 — $-0.25 | -5% YoY | 8 |
Latest Reports
BULLISH
Press
7/10
Context Therapeutics amended its license agreement with BioAtla for CT-202, buying out all future milestone and royalty
May 18, 2026
MIXED
PRESS-RELEASE
5/10
Context Therapeutics reported Q1 2026 EPS of -$0.09, beating consensus of -$0.12 by 25%. The pre-revenue biotech highlig
May 6, 2026
NEUTRAL
8-K
2/10
Context Therapeutics resolved a stockholder class action lawsuit challenging its charter provisions. Under a court-appro
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $5.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $747.2K | ADD |
| BANK OF AMERICA CORP | $1.4K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 19, 2026 | Levit Alex | A | $0.00 |
| Feb 19, 2026 | Minai-Azary Jennifer | A | $0.00 |
| Feb 19, 2026 | Chagin Karen | A | $0.00 |
| Feb 19, 2026 | Lehr Martin | A | $0.00 |
Reddit Sentiment
40°
Cool
Bearish
Neutral
Bullish
3 institutional holders with $6.3M total value (4,295,171 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,785,909 | $5.6M | 88.1% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 508,329 | $747.2K | 11.8% | ADD +58.8% |
| 3 | BANK OF AMERICA CORP /DE/ | 933 | $1.4K | 0.0% | DOUBLED +115.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 320,127 | 508,329 | +58.8% | $747.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 434 | 933 | +115.0% | $1.4K | 2025-Q4 |
| UBS Group AG | DOUBLED | 370 | 7,382 | +1895.1% | $7.2K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 100 | 3,500 | +3400.0% | $2.3K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 338,435 | 425,500 | +25.7% | $260.4K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 699,129 | 432 | -99.9% | $264.00 | 2025-Q1 |
| MORGAN STANLEY | TRIM | 227 | 100 | -55.9% | $61.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 29,900 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 1,717 | 699,129 | +40618.1% | $734.1K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 66,000 | 338,435 | +412.8% | $355.4K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 29,900 | — | $31.4K | 2024-Q4 |
4 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 19, 2026 | Levit Alex C. | Chief Legal Officer, Corp. Sec | A | 270,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Minai-Azary Jennifer Lynn | Chief Financial Officer | A | 275,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Chagin Karen Deborah | Chief Medical Officer | A | 290,000 | $0.00 | $0.00 |
| Feb 19, 2026 | Lehr Martin A. | Chief Executive Officer | A | 815,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 4.7/10.
MIXED
PRESS-RELEASE
5/10
Context Therapeutics reported Q1 2026 EPS of -$0.09, beating consensus of -$0.12 by 25%. The pre-rev
May 6, 2026
NEUTRAL
8-K
2/10
Context Therapeutics resolved a stockholder class action lawsuit challenging its charter provisions.
May 1, 2026
BULLISH
8-K
7/10
Context Therapeutics Inc. (CNTX) announced that the FDA has granted Fast Track designation to its in
Apr 2, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 4 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.00 mean target
+153.7% upside
Strong Buy (1.30)
$4.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $2.37 |
| Target Low | $4.00 |
| Target Mean | $6.00 |
| Target Median | $5.50 |
| Target High | $9.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.30) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.09 | $-0.10 | $-0.07 | -1.4% | +20.3% | 6↑ 0↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$-0.10 | $-0.11 | $-0.07 | 2.5% | +15.6% | 5↑ 1↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-0.39 | $-0.43 | $-0.30 | -3.3% | +15.7% | 4↑ 1↓ | $0.0B | 0.0% | 8 |
| Next FY 2027-12-31 |
$-0.41 | $-0.49 | $-0.25 | -4.8% | +11.1% | 3↑ 2↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.091 | |
| 7d ago | $-0.114 | +0.023 |
| 30d ago | $-0.114 | +0.023 |
| 60d ago | $-0.113 | +0.021 |
| 90d ago | $-0.111 | +0.020 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 24, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Mar 24, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Dec 22, 2025 | Jones Trading | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
40°
Cool
Bearish
Neutral
Bullish
1 mentions
0 bullish
1 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 10, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
May 18, 2026
contract
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
<p align="center"><em>Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license</em><
May 13, 2026
earnings_calendar
CNTX Q1 2026 Earnings Scheduled — 2026-05-13
May 6, 2026
earnings
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
<p align="center"><em>Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026</em></p>
May 1, 2026
earnings_calendar
CNTX Q1 2026 Earnings Scheduled — 2026-05-01
Apr 2, 2026
other
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
<p align="center"><em>Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC</em></p>
Mar 25, 2026
earnings_calendar
CNTX Q4 2025 Earnings After Market Close — 2026-03-25
Mar 23, 2026
earnings
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
<p align="center"><em>Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026</em></p>
Mar 19, 2026
routine
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
<p align="left">PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-s